Nautilus Biotechnology (NAUT) Long-Term Investments (2020 - 2026)

Nautilus Biotechnology has disclosed Long-Term Investments across 7 years of filings, most recently posting $47.5 million for Q1 2026.

• Long-Term Investments for Q1 2026 came in at $47.5 million, down 12.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $47.5 million (down 12.07% YoY), and the FY2025 annual result was $52.7 million, down 30.97% from the prior year.
• Long-Term Investments came in at $47.5 million for Q1 2026 at Nautilus Biotechnology, down from $52.7 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $134.6 million in Q1 2023 to a low of $24.9 million in Q1 2022.
• The 5-year median for Long-Term Investments is $65.7 million (2022), against an average of $71.1 million.
• Peak annual rise in Long-Term Investments reached 689.01% in 2022, while the deepest fall reached 83.34% in 2022.
• Nautilus Biotechnology's Long-Term Investments stood at $129.2 million in 2022, then retreated by 29.82% to $90.6 million in 2023, then decreased by 15.71% to $76.4 million in 2024, then sank by 30.97% to $52.7 million in 2025, then fell by 9.92% to $47.5 million in 2026.
• The last three Long-Term Investments figures came in at $47.5 million (Q1 2026), $52.7 million (Q4 2025), and $37.1 million (Q3 2025), per Business Quant data.